Baxalta in talks to buy U.S. hematology-oncology specialist - Bloomberg
August 28, 2015 at 13:31 PM EDT
Aug 28 (Reuters) - Drugmaker Baxalta Inc is working with bankers to buy a U.S.-based hematology and oncology specialist valued at about $2 billion, Bloomberg reported, citing people familiar with the matter.